Literature DB >> 18272962

Cisplatin nephrotoxicity: mechanisms and renoprotective strategies.

N Pabla1, Z Dong.   

Abstract

Cisplatin is one of the most widely used and most potent chemotherapy drugs. However, side effects in normal tissues and organs, notably nephrotoxicity in the kidneys, limit the use of cisplatin and related platinum-based therapeutics. Recent research has shed significant new lights on the mechanism of cisplatin nephrotoxicity, especially on the signaling pathways leading to tubular cell death and inflammation. Renoprotective approaches are being discovered, but the protective effects are mostly partial, suggesting the need for combinatorial strategies. Importantly, it is unclear whether these approaches would limit the anticancer effects of cisplatin in tumors. Examination of tumor-bearing animals and identification of novel renoprotective strategies that do not diminish the anticancer efficacy of cisplatin are essential to the development of clinically applicable interventions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272962     DOI: 10.1038/sj.ki.5002786

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  514 in total

Review 1.  Drug-induced acute kidney injury in children.

Authors:  Lauren N Faught; Michael J E Greff; Michael J Rieder; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

2.  Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer.

Authors:  Navjotsingh Pabla; Guie Dong; Man Jiang; Shuang Huang; M Vijay Kumar; Robert O Messing; Zheng Dong
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 3.  Developing better mouse models to study cisplatin-induced kidney injury.

Authors:  Cierra N Sharp; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-19

4.  Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment.

Authors:  Rodney J Hunter; Makala B Pace; Kimberly A Burns; Catherine C Burke; Deborah A Gonzales; Nicki F Webb; Charles F Levenback; Anuja Jhingran; Crystal Parker; Mark F Munsell; Judith A Smith
Journal:  Support Care Cancer       Date:  2009-01-27       Impact factor: 3.603

5.  Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy.

Authors:  Shutao Guo; Lei Miao; Yuhua Wang; Leaf Huang
Journal:  J Control Release       Date:  2013-11-23       Impact factor: 9.776

6.  Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death.

Authors:  Hao Pan; Partha Mukhopadhyay; Mohanraj Rajesh; Vivek Patel; Bani Mukhopadhyay; Bin Gao; György Haskó; Pál Pacher
Journal:  J Pharmacol Exp Ther       Date:  2008-12-12       Impact factor: 4.030

7.  Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas.

Authors:  Osama A Elkashty; Ramy Ashry; Ghada Abu Elghanam; Hieu M Pham; Xinyun Su; Camille Stegen; Simon D Tran
Journal:  Med Oncol       Date:  2018-08-04       Impact factor: 3.064

Review 8.  A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.

Authors:  Daniel J Crona; Aimee Faso; Tomohiro F Nishijima; Kathleen A McGraw; Matthew D Galsky; Matthew I Milowsky
Journal:  Oncologist       Date:  2017-04-24

9.  Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.

Authors:  Yoshitaka Saito; Masaki Kobayashi; Takehiro Yamada; Kumiko Kasashi; Rio Honma; Satoshi Takeuchi; Yasushi Shimizu; Ichiro Kinoshita; Hirotoshi Dosaka-Akita; Ken Iseki
Journal:  Support Care Cancer       Date:  2016-10-03       Impact factor: 3.603

10.  Epoxyeicosatrienoic acids prevent cisplatin-induced renal apoptosis through a p38 mitogen-activated protein kinase-regulated mitochondrial pathway.

Authors:  Yingmei Liu; Xiaodan Lu; Sinh Nguyen; Jean L Olson; Heather K Webb; Deanna L Kroetz
Journal:  Mol Pharmacol       Date:  2013-10-03       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.